Author: [email protected]
-
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively
-
Biodesix Announces impactful Clinical Data on the Primary Immune Response (PIR) test at the IASLC 2022 Therapies of Lung Cancer Meeting
BOULDER, Colo.— (BUSINESS WIRE)—March 3, 2022— Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provided two classifications of…
-
Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022
BOULDER, Colo.–(BUSINESS WIRE)–Feb. 22, 2022– Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Executive Officer was named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022. The annual list recognizes the most accomplished executives in the biotech industry.
-
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment
-
Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors
BOULDER, Colo.–(BUSINESS WIRE)–Dec. 8, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company’s board of directors. Dr. Kayyem’s diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served…
-
Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer
View as PDF » MEMPHIS, Tenn.–(BUSINESS WIRE)–Dec. 1, 2021– Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the…
-
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
View as PDF » Data published shows the VeriStrat proteomic test improved overall patient survival by better informing physicians on the selection of immunotherapies to optimally treat NSCLC patients BOULDER, Colo.–(BUSINESS WIRE)–Nov. 18, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published…
-
Biodesix Announces Third Quarter 2021 Results and Highlights
View as PDF » Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET BOULDER, Colo.–(BUSINESS WIRE)–Nov. 15, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its…
-
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 12, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 –…
-
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 11, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021. Canaccord Genuity Virtual…